<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-id journal-id-type="publisher-id">PJMS</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26649008</article-id><article-id pub-id-type="pmc">4641277</article-id><article-id pub-id-type="publisher-id">PJMS-31-1172</article-id><article-id pub-id-type="doi">10.12669/pjms.315.7921</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic effects of probiotics on neonatal jaundice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Wenbin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1"/><xref ref-type="author-notes" rid="fn1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Huajun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="author-notes" rid="fn1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Taisen</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Xueqing</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Wenbin Liu, Department of Pediatrics, Chengdu Military General Hospital, Chengdu 610083, PR China</aff><aff id="aff2"><label>2</label>Huajun Liu, Department of Pediatrics, Chengdu Military General Hospital, Chengdu 610083, PR China</aff><aff id="aff3"><label>3</label>Taisen Wang, Department of Pediatrics, Chengdu Military General Hospital, Chengdu 610083, PR China</aff><aff id="aff4"><label>4</label>Xueqing Tang, Department of Pediatrics, Chengdu Military General Hospital, Chengdu 610083, PR China</aff><author-notes><corresp id="cor1">
Correspondence: Wenbin Liu, MM. Department of Pediatrics, Chengdu Military General Hospital, Chengdu 610083, PR China. E-mail: <email xlink:href="liuwbdp@yeah.net">liuwbdp@yeah.net</email><email xlink:href="liuwenbinliuyi@163.com">liuwenbinliuyi@163.com</email></corresp><fn id="fn1"><p><bold><italic>Note:</italic></bold> Wenbin Liu and Huajun Liu contributed equally to this study.</p></fn></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2015</year></pub-date><volume>31</volume><issue>5</issue><fpage>1172</fpage><lpage>1175</lpage><history><date date-type="received"><day>08</day><month>4</month><year>2015</year></date><date date-type="rev-recd"><day>27</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objective:</title><p>To evaluate the therapeutic effects of probiotics on neonatal jaundice and the safety.</p></sec><sec id="st2"><title>Methods:</title><p>Sixty-eight neonates with jaundice were divided into a control group and a treatment group (n=34) randomly, and treated by blue light phototherapy and that in combination with probiotics. The serum bilirubin levels were detected before and 1, 4, 7 days after treatment. The time when therapy showed effects and jaundice faded, clinical outcomes as well as adverse reactions were recorded. The categorical data were expressed as (<inline-graphic xlink:href="PJMS-31-1172-g001.jpg"/>&#x000b1;s) and compared by t test. The numerical data were expressed as (case, %) and compared by &#x003c7;&#x000b2; test. P&#x0003c;0.05 was considered statistically significant.</p></sec><sec id="st3"><title>Results:</title><p>Serum bilirubin levels of the two groups were similar before treatment (P&#x0003e;0.05). The levels significantly decreased 1, 4 and 7 days after treatment (P&#x0003c;0.05), but there was no significant inter-group difference on the post-treatment 1st day (P&#x0003e;0.05). The treatment group underwent more significant decreases on the 4th and 7th days than the control group did (P=0.002, 0.001). In the treatment group, the therapy exerted effects on (1.0&#x000b1;0.5) d and jaundice faded on (3.8&#x000b1;1.7) d, which were (2.6&#x000b1;0.6) d and (5.3&#x000b1;2.1) d respectively in the control group (P=0.001, 0.002). The effective rate of the treatment group significantly exceeded that of the control group (P=0.002). There were no obvious adverse reactions in either group.</p></sec><sec id="st4"><title>Conclusions:</title><p>Probiotics lowered the serum bilirubin levels of neonates with jaundice rapidly, safely and significantly, and accelerated jaundice fading as well. This method is worthy of application in clinical practice.</p></sec></abstract><kwd-group><title>KEY WORDS</title><kwd>Bifid triple viable</kwd><kwd>Jaundice</kwd><kwd>Neonate</kwd><kwd>Probiotics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>In clinical practice, neonatal jaundice is very common, which is mainly manifested as yellowish pigmentation of mucous membranes due to hyperbilirubinemia.<xref rid="ref1" ref-type="bibr">1</xref> The incidence of neonatal jaundice remains high because of infections, genetic factors and premature birth. If not timely treated, neonates may be subjected to pneumonia or septicemia that severely endangers normal development of intelligence, hearing and the nervous system, or leads to permanent sequelae.<xref rid="ref2" ref-type="bibr">2</xref></p><p>Besides blue light phototherapy, touching and drugs, probiotics have also been used to enhance immunity mainly by regulating bacterial colonies. They can form a biological barrier by specifically binding intestinal epithelial cells through teichoic acid. Therefore, particular attention has been paid to the use of probiotics in treating neonatal jaundice. Therefore, the aim of this study was to evaluate the therapeutic effects of probiotics on neonatal jaundice and the safety, providing clinical evidence for future treatment.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><sec id="sec2-1"><title>General Information</title><p>Sixty-eight neonates with jaundice who were treated in Chengdu Military General Hospital (Chengdu, China) from July 2012 to August 2014 were selected in this study. This study was approved by the ethics committee of our hospital. Written consent has been obtained from the legal guardians of these neonates.</p><p>They were diagnosed according to the criteria for neonatal jaundice in &#x0201c;Zhu Futang Practice of Pediatrics (7th Edition)&#x0201d;<xref rid="ref3" ref-type="bibr">3</xref> based on the transcutaneous bilirubin levels (&#x0003e;12.9 mg/dL, performed by NJ33A infants tester). Then they were randomly divided into a control group and a treatment group (n=34).</p><p>The control group comprised 20 boys and 14 girls with the gestational ages of 38-42 weeks (average: 39.5&#x000b1;0.3). They were aged 5-18.2 d, (11.2&#x000b1;1.3) d in average. Their birth weights ranged from 3.12 to 4.21 kg, (3.75&#x000b1;0.21) kg in average. Causes of jaundice: 10 cases of hemolytic jaundice, 8 cases of infectious jaundice, 8 cases of dysmetabolic jaundice and 8 cases of breast milk jaundice. The treatment group consisted of 22 boys and 12 girls with the gestational ages of 37-41 weeks (average: 39.0&#x000b1;0.4). They were aged 4.2-18.5 d, (11.3&#x000b1;1.2) d in average. Their birth weights ranged from 3.20 to 4.37 kg, (3.86&#x000b1;0.23) kg in average. Causes of jaundice: 8 cases of hemolytic jaundice, 11 cases of infectious jaundice, 8 cases of dysmetabolic jaundice and 7 cases of breast milk jaundice. The two groups had similar age, gender ratio and pretreatment bilirubin levels (P&#x0003e;0.05).</p></sec><sec id="sec2-2"><title>Treatment Methods</title><p>The control group was treated by blue light phototherapy for 3-5 d, 12-24 hour per day. Meanwhile, they were intravenously infused with phenobarbital (Shanghai Sine Pharmaceutical Laboratories Co., Ltd., National Medicine Permit No. H31022038, 30 mg &#x000d7; 100 tablets, batch No. 20130321; dose: 5-8 mg/kg body weight each time, 3 times per day) and 5% albumin (dose: 10-15 ml/kg body weight, once per day).</p><p>Based on these, the treatment group was also orally administered with bifid triple viable (Shanghai Sine Pharmaceutical Laboratories Co., Ltd., National Medicine Permit No. S10950032, 0.2 g &#x000d7; 24 s, batch No. 20120524; dose: 2 g/d, completed in three or four times).</p></sec><sec id="sec2-3"><title>Observation Indices</title><p>Fasting venous bloods (3 ml) were drawn before and 1, 4 and 7 days after treatment to detect serum bilirubin levels. After centrifugation at 3000 r/minutes for 10 minutes, the serum was collected and detected by using Mindray BS400 Automatic Biochemical Analyzer with the oxidation method.<xref rid="ref4" ref-type="bibr">4</xref> The time when therapy showed effects and jaundice faded, clinical outcomes and adverse reactions were recorded. Time of exerting effects: The time of icteric index that was measured with a transcutaneous jaundice meter (JM-103, Chengdu Beisida Instruments Co., Ltd.) decreased.<xref rid="ref5" ref-type="bibr">5</xref> Clinical outcomes: Markedly effective: Fading of yellowish pigmentation and obvious decrease in serum bilirubin level. Effective: Basic fading of yellowish pigmentation and moderate decrease in serum bilirubin level. Ineffective: Unchanged yellowish pigmentation and maintained or elevated serum bilirubin level.</p></sec><sec id="sec2-4"><title>Statistical Analysis</title><p>All data were analyzed by SPSS18.0. The categorical data were expressed as (<inline-graphic xlink:href="PJMS-31-1172-g002.jpg"/>&#x000b1;s) and compared by t test. The numerical data were expressed as (case, %) and compared by &#x003c7;&#x000b2; test. P&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-5"><title>Serum Bilirubin Levels</title><p>Serum bilirubin levels of the two groups were similar before treatment (P&#x0003e;0.05). The levels were significantly decreased 1, 4 and 7 days after treatment (P&#x0003c;0.05), but there was no significant inter-group difference on the post-treatment 1st day (P&#x0003e;0.05). The treatment group underwent more significant decreases on the 4th and 7th days than the control group did (P&#x0003c;0.05) (<xref ref-type="table" rid="T1">Table-I</xref>).</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Serum bilirubin levels before and after treatment (<inline-graphic xlink:href="PJMS-31-1172-g003.jpg"/>&#x000b1;s, &#x003bc;mol/L).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Before</th><th align="left" rowspan="1" colspan="1">1 d after</th><th align="left" rowspan="1" colspan="1">4 d after</th><th align="left" rowspan="1" colspan="1">7 d after</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control (n=34)</td><td align="left" rowspan="1" colspan="1">351&#x000b1;48</td><td align="left" rowspan="1" colspan="1">312&#x000b1;41a</td><td align="left" rowspan="1" colspan="1">195&#x000b1;40a</td><td align="left" rowspan="1" colspan="1">108&#x000b1;21a</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment (n=34)</td><td align="left" rowspan="1" colspan="1">347&#x000b1;52</td><td align="left" rowspan="1" colspan="1">309&#x000b1;42a</td><td align="left" rowspan="1" colspan="1">155&#x000b1;37a</td><td align="left" rowspan="1" colspan="1">79&#x000b1;18a</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="left" rowspan="1" colspan="1">0.367</td><td align="left" rowspan="1" colspan="1">0.876</td><td align="left" rowspan="1" colspan="1">2.747</td><td align="left" rowspan="1" colspan="1">5.918</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.05</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Compared with the levels before treatment, aP&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-6"><title>Clinical Indices</title><p>In the treatment group, the therapy exerted effects on (1.0&#x000b1;0.5) d and jaundice faded on (3.8&#x000b1;1.7) d, which were (2.6&#x000b1;0.6) d and (5.3&#x000b1;2.1) d respectively in the control group (P&#x0003c;0.05). In addition, the two groups had significantly different numbers and times of blue light phototherapy (P&#x0003c;0.05) (<xref ref-type="table" rid="T2">Table-II</xref>).</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Changes of clinical indices (<inline-graphic xlink:href="PJMS-31-1172-g004.jpg"/>&#x000b1;s).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Group</th><th align="center" valign="top" rowspan="1" colspan="1">Time of exerting effect (d)</th><th align="center" valign="top" rowspan="1" colspan="1">Time of jaundice fading (d)</th><th align="center" valign="top" rowspan="1" colspan="1">No. of blue light phototherapy</th><th align="left" valign="top" rowspan="1" colspan="1">Time of blue light phototherapy (h)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control (n=34)</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;0.6</td><td align="center" rowspan="1" colspan="1">5.3&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">2.69&#x000b1;0.96</td><td align="left" rowspan="1" colspan="1">53.12&#x000b1;19.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment (n=34)</td><td align="center" rowspan="1" colspan="1">1.0&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">3.8&#x000b1;1.7</td><td align="center" rowspan="1" colspan="1">2.17&#x000b1;0.76</td><td align="left" rowspan="1" colspan="1">39.74&#x000b1;9.57</td></tr><tr><td align="left" rowspan="1" colspan="1">t</td><td align="center" rowspan="1" colspan="1">3.750</td><td align="center" rowspan="1" colspan="1">2.121</td><td align="center" rowspan="1" colspan="1">2.384</td><td align="left" rowspan="1" colspan="1">3.059</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">0.004</td></tr></tbody></table></table-wrap></sec><sec id="sec2-7"><title>Clinical Outcomes</title><p>The effective rate of the treatment group significantly exceeded that of the control group (P&#x0003c;0.05) (<xref ref-type="table" rid="T3">Table-III</xref>).</p><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Clinical outcomes (case).</p></caption><table frame="hsides" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Markedly effective</th><th align="center" rowspan="1" colspan="1">Effective</th><th align="center" rowspan="1" colspan="1">Ineffective</th><th align="center" rowspan="1" colspan="1">Effective rate (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Control (n=34)</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">79.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment (n=34)</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">91.18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003c7;&#x000b2;</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10.65</td></tr><tr><td align="left" rowspan="1" colspan="1">P</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.002</td></tr></tbody></table></table-wrap></sec><sec id="sec2-8"><title>Adverse Reactions</title><p>Neither group was subjected to obvious adverse reactions, indicating the treatment was safe.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Neonatal jaundice, which is common in clinical practice, can mainly be classified as physiological and pathological ones. The former does not need special treatment,<xref rid="ref6" ref-type="bibr">6</xref> but the latter, which originates from various factors, easily leads to bilirubin encephalopathy and even brain damage or death. Therefore, it should be timely treated. Mainly manifested as hyperbilirubinemia, neonatal jaundice is caused by enhanced intestinal-hepatic circulation of bilirubin owing to high content and activity of &#x003b2;-glucuronidase (&#x003b2;-GD).<xref rid="ref7" ref-type="bibr">7</xref> &#x003b2;-GD can hydrolyze the bound bilirubin into unbound one and glucuronide, and the unbound bilirubin boost intestinal-hepatic circulation after being absorbed by intestinal cells.<xref rid="ref8" ref-type="bibr">8</xref> Recently, intestinal flora, which are diverse and structurally complex, have attracted wide attention as the &#x0201c;Second Human Genome&#x0201d;.<xref rid="ref9" ref-type="bibr">9</xref></p><p>The roles of probiotics in human body have been explained by different pharmacological mechanisms. For example, they can rapidly increase the number of anaerobic bacterial colonies, promote the recovery of intestinal microflora balance, and resist infections in some cases.<xref rid="ref10" ref-type="bibr">10</xref> On the other hand, intestinal probiotics affect the amount of bilirubin in the enterohepatic circulation by reducing the degradation of bound bilirubin.<xref rid="ref11" ref-type="bibr">11</xref> Meanwhile, they are able to stimulate intestinal peristalsis, which also benefits the elimination of bilirubin. It has previously been reported that oral administration of probiotics showed markedly better effects than those of routine blue light phototherapy.<xref rid="ref12" ref-type="bibr">12</xref> Furthermore, the establishment of intestinal probiotic bacteria can perfect the human immune system, thereby affecting the activation and proliferation of sIgA and T lymphocytes as an analogue to active immunity.<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref14" ref-type="bibr">14</xref> As a result, these exert obvious beneficial effects on neonates.<xref rid="ref15" ref-type="bibr">15</xref></p><p>In this study, neonatal jaundice was treated by using bifid triple viable containing <italic>Lactobacillus bulgaricus</italic>, live <italic>Bifidobacterium</italic> and <italic>Streptococcus thermophilus</italic> that are normal microorganisms in the human intestinal tract.<xref rid="ref16" ref-type="bibr">16</xref> After being orally taken, they grew in the intestinal tract to produce vitamins and to help the proliferation of normal bacterial colonies. Serum bilirubin levels of the two groups were similar before treatment (P&#x0003e;0.05). The levels were significantly reduced 1, 4 and 7 days after treatment (P&#x0003c;0.05), but there was no significant inter-group difference on the post-treatment 1st day (P&#x0003e;0.05). The treatment group underwent more significant decreases on the 4th and 7th days than the control group did (P&#x0003c;0.05). In the treatment group, the therapy exerted effects on (1.0&#x000b1;0.5) d and jaundice faded on (3.8&#x000b1;1.7) d, which were (2.6&#x000b1;0.6) d and (5.3&#x000b1;2.1) d respectively in the control group, with significant differences (P&#x0003c;0.05). Moreover, the two groups had significantly different numbers and times of blue light phototherapy (P&#x0003c;0.05).</p><p>Accordingly, bifid triple viable accelerated jaundice fading by rapidly lowering the bilirubin level, with quick recovery also. Probably, this agent facilitated the growth of normal bacterial colonies in the intestinal tract of neonates, and the resulting metabolites effectively corrected the slightly alkaline environment, thus weakening the activity of &#x003b2;-GD and preventing it from binding and hydrolyzing bilirubin.<xref rid="ref17" ref-type="bibr">17</xref> Furthermore, the activities of liver enzymes were also enhanced, which benefited the excretion and binding of bilirubin.<xref rid="ref18" ref-type="bibr">18</xref> The effective rate of the treatment group was significantly higher than that of the control group (P&#x0003c;0.05). Since neither group was subjected to obvious adverse reactions, the treatment was fairly safe.</p><p>In summary, probiotics were able to treat neonatal jaundice quickly, safely and significantly, without discernible side effects. Hence, this method is worthy of application in clinical practice.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold><italic>Declaration of interest:</italic></bold> The authors have no conflicts of interest to declare.</p></fn><fn fn-type="supported-by"><p><bold><italic>Source of funding:</italic></bold> None.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>ML</given-names></name><name><surname>Dennis</surname><given-names>BL</given-names></name></person-group><article-title>Hyperbilirubinemia in the term newborn</article-title><source>Am Fam Physician</source><year>2002</year><volume>65</volume><issue>4</issue><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">11871676</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjarnason</surname><given-names>I</given-names></name><name><surname>MacPherson</surname><given-names>A</given-names></name><name><surname>Hollander</surname><given-names>D</given-names></name></person-group><article-title>Intestinal permeability: an overview</article-title><source>Gastroenterology</source><year>1995</year><volume>108</volume><issue>5</issue><fpage>1566</fpage><lpage>1581</lpage><pub-id pub-id-type="pmid">7729650</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="editor"><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Jiang</surname><given-names>ZF</given-names></name></person-group><article-title>Zhu Futang Practice of Pediatrics</article-title><source>People&#x02019;s Medical Publishing House Co., Ltd</source><year>2002</year><edition>7th Edition</edition></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>M</given-names></name><name><surname>Schinasi</surname><given-names>DA</given-names></name><name><surname>Lavelle</surname><given-names>J</given-names></name><name><surname>Boorstein</surname><given-names>N</given-names></name><name><surname>Zorc</surname><given-names>JJ</given-names></name></person-group><article-title>Management of neonates with hyperbilirubinemia: Improving timeliness of care using a clinical pathway</article-title><source>Pediatrics</source><year>2012</year><volume>130</volume><issue>6</issue><fpage>e1688</fpage><lpage>1694</lpage><comment>doi: 10.1542/peds.2012-1156</comment><pub-id pub-id-type="pmid">23147974</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salinas</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez-Garrig&#x000f3;s</surname><given-names>M</given-names></name><name><surname>Lugo</surname><given-names>J</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>M</given-names></name><name><surname>Flors</surname><given-names>L</given-names></name><name><surname>Leiva-Salinas</surname><given-names>C</given-names></name></person-group><article-title>Diagnostic accuracy of icteric index to detect abnormal total bilirubin values</article-title><source>J Clin Pathol</source><year>2012</year><volume>65</volume><issue>10</issue><fpage>928</fpage><fpage>933</fpage><comment>doi: 10.1136/jclinpath-2012-200811</comment><pub-id pub-id-type="pmid">22859392</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bertini</surname><given-names>G</given-names></name><name><surname>Dani</surname><given-names>C</given-names></name></person-group><article-title>Bilirubin Metabolism, Unconjugated Hyperbilirubinemia, Physiological Neonatal Jaundice</article-title><source>Neonatol</source><year>2012</year><publisher-name>Springer-Verlag Milan</publisher-name><fpage>608</fpage><lpage>610</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>TN</given-names></name></person-group><article-title>Developmental physiology of late &#x00026; moderate prematurity</article-title><source>Semin Fetal Neonatal Med</source><year>2012</year><volume>17</volume><issue>3</issue><fpage>126</fpage><lpage>131</lpage><comment>doi: 10.1016/j.siny.2012.01.010</comment><pub-id pub-id-type="pmid">22317884</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chowdhury</surname><given-names>JR</given-names></name><name><surname>Chowdhury</surname><given-names>NR</given-names></name></person-group><article-title>Bilirubin metabolism: Applied physiology</article-title><source>Curr Pediatr</source><year>2006</year><volume>16</volume><issue>1</issue><fpage>70</fpage><lpage>74</lpage><comment>doi: 10.1016/j.cupe.2005.10.002</comment></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SF</given-names></name><name><surname>Xu</surname><given-names>YZ</given-names></name><name><surname>Ai</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>JL</given-names></name></person-group><article-title>Intestinal microbial community diversity in neonatal necrotizing enterocolitis analyzed by PCR-DGGE</article-title><source>Chongqing Medicine</source><year>2012</year><volume>41</volume><issue>29</issue><fpage>3026</fpage><lpage>3029</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>MJ</given-names></name></person-group><article-title>[Management of Hyperbilirubinemia in Newborns and Related Issues]</article-title><source>Journal of Applied Clinical Pediatrics</source><year>2011</year><volume>14</volume><issue>26</issue><fpage>1132</fpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffarelli</surname><given-names>C</given-names></name><name><surname>Santamaria</surname><given-names>F</given-names></name><name><surname>Vottero</surname><given-names>A</given-names></name><name><surname>Dascola</surname><given-names>CP</given-names></name><name><surname>Mirra</surname><given-names>V</given-names></name><name><surname>Sperli</surname><given-names>F</given-names></name><etal/></person-group><article-title>Progress in pediatrics in 2013: choices in allergology, endocrinology, gastroenterology, hypertension, infectious diseases, neonatology, neurology, nutrition and respiratory tract illnesses</article-title><source>Ital J Pediatr</source><year>2014</year><volume>40</volume><issue>1</issue><fpage>62</fpage><comment>doi: 10.1186/1824-7288-40-62</comment><pub-id pub-id-type="pmid">25015124</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>HY</given-names></name></person-group><article-title>Effect of oral probiotics on treatment of neonates with hyperbilirubinemia and its influence on immune function</article-title><source>J Clin Med Pract</source><year>2015</year><volume>19</volume><issue>7</issue><fpage>104</fpage><lpage>106</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>DK</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name></person-group><article-title>Metalloporphyrins in the management of neonatal hyperbilirubinemia</article-title><source>Semin Fetal Neonatal Med</source><year>2009</year><volume>15</volume><issue>3</issue><fpage>164</fpage><lpage>168</lpage><comment>doi: 10.1016/j.siny.2009.11.004</comment><pub-id pub-id-type="pmid">20006567</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengmark</surname><given-names>S</given-names></name></person-group><article-title>Econutrition and health maintenance-a new concept to prevent GI inflammation, ulceration and sepsis</article-title><source>Clin Nutr</source><year>1996</year><volume>15</volume><issue>1</issue><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16843987</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayes</surname><given-names>N</given-names></name><name><surname>Seehofer</surname><given-names>D</given-names></name><name><surname>Theruvath</surname><given-names>T</given-names></name><name><surname>Mogl</surname><given-names>M</given-names></name><name><surname>Langrehr</surname><given-names>JM</given-names></name><name><surname>N&#x000fc;ssler</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial</article-title><source>An Surg</source><year>2007</year><volume>246</volume><issue>1</issue><fpage>36</fpage><lpage>41</lpage><comment>doi: 10.1097/01.sla.0000259442.78947.19</comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>N</given-names></name></person-group><article-title>The effect of bifid triple viable on immune function of patients with ulcerative colitis</article-title><source>Gastroenterol Res Pract</source><year>2012</year><volume>2012</volume><fpage>404752</fpage><comment>doi: 10.1155/2012/404752</comment><pub-id pub-id-type="pmid">22927836</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>J</given-names></name><name><surname>Ca&#x000f1;abate</surname><given-names>F</given-names></name><name><surname>Sempere</surname><given-names>L</given-names></name><name><surname>Vela</surname><given-names>F</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>AR</given-names></name><name><surname>Narbona</surname><given-names>E</given-names></name><etal/></person-group><article-title>Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2012</year><volume>54</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><comment>doi: 10.1097/MPG.0b013e3182333f18</comment><pub-id pub-id-type="pmid">21873895</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minomo</surname><given-names>A</given-names></name><name><surname>Ishima</surname><given-names>Y</given-names></name><name><surname>Chuang</surname><given-names>VT</given-names></name><name><surname>Suwa</surname><given-names>Y</given-names></name><name><surname>Kragh-Hansen</surname><given-names>U</given-names></name><name><surname>Narisoko</surname><given-names>T</given-names></name><etal/></person-group><article-title>Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment</article-title><source>Biochim Biophys Acta</source><year>2013</year><volume>1830</volume><issue>4</issue><fpage>2917</fpage><lpage>2923</lpage><comment>doi: 10.1016/j.bbagen.2013.01.006</comment><pub-id pub-id-type="pmid">23328494</pub-id></element-citation></ref></ref-list><sec id="sec1-5"><title/><sec id="sec2-9"><title>Authors&#x02019; Contributions</title><p><bold>WL &#x00026; HL:</bold> Study design and manuscript writing.</p><p><bold>TW &#x00026; XT:</bold> Data collection and analysis.</p></sec></sec></back></article>